CIP
SYRE icon

Chartwell Investment Partners’s Spyre Therapeutics SYRE Stock Holding History

Chartwell Investment Partners’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,835
Closed -$259K – 439
2024
Q1 		$259K Buy
+6,835
New +$198K 0.01% 406

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Chartwell Investment Partners's SYRE Position: Q2 2024 in Review

Chartwell Investment Partners sold out of Spyre Therapeutics (SYRE) in Q2 2024, closing a stake of 6,835 shares — an estimated $259K sold.

Chartwell Investment Partners first reported a position in SYRE in Q1 2024 and held it in 1 quarter. The position peaked at $259K in Q1 2024. 107 funds tracked by Wall St. Rank hold SYRE as of Q2 2024.

  • Chartwell Investment Partners reported no remaining Spyre Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Chartwell Investment Partners sold 6,835 Spyre Therapeutics shares in Q2 2024, an estimated $259K.
  • Chartwell Investment Partners first reported a position in Spyre Therapeutics in Q1 2024 and held it in 1 quarter.
  • Chartwell Investment Partners's Spyre Therapeutics position peaked at $259K in Q1 2024.
  • 107 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2024.

Based on Chartwell Investment Partners's 13F filing for Q2 2024, filed 8 Aug 2024.